Glaukos (NYSE: GKOS) president sells 4,502 shares after option exercise

Q: How many Glaukos (GKOS) shares did the insider sell and at what price?

Joseph E. Gilliam sold 4,502 Glaukos common shares at a weighted average price of $124.65 per share, with individual trades between $124.47 and $124.75 .

Q: What portion of Joseph E. Gilliam’s GKOS holdings are restricted stock units?

His reported holdings include 62,605 restricted stock units that have not yet vested or been delivered.

Q: What are the details of the Glaukos stock options exercised by the insider?

He exercised stock options covering 2,602 and 1,900 shares of Glaukos common stock at an exercise price of $55.18 per share, from grants dated March 24, 2022 that were tied to multi-year performance goals.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Glaukos Corporation’s president and COO, Joseph E. Gilliam, reported option exercises and a share sale. On January 21, 2026, he exercised stock options for 2,602 and 1,900 shares of common stock at an exercise price of $55.18 per share. This resulted in the acquisition of 4,502 common shares, which were then sold the same day at a weighted average price of $124.65 per share, in trades ranging from $124.47 to $124.75, under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, he directly holds 92,366 shares of common stock, including 62,605 restricted stock units that have not yet vested or been delivered.

Insider Trade Summary

Net Seller: 4,502 shares ($561,174)

Net Sell 4 txns

Insider Gilliam Joseph E

Role PRESIDENT & COO

Sold 4,502 shs ($561K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,602	$0.00	--
Exercise	Stock Option (Right to Buy)	1,900	$0.00	--
Exercise	Common Stock	4,502	$55.18	$248K
Sale	Common Stock	4,502	$124.65	$561K

Holdings After Transaction: Stock Option (Right to Buy) — 62,411 shares (Direct); Common Stock — 96,868 shares (Direct)

Footnotes (1)

Includes 62,605 restricted stock units that have not yet vested or been delivered to the Reporting Person. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. This transaction was executed in multiple trades at prices ranging from $124.47 to $124.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

01/23/2026 - 08:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilliam Joseph E

(Last)

(First)

(Middle)

C/O GLAUKOS CORPORATION

ONE GLAUKOS WAY

(Street)

ALISO VIEJO

92656

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT & COO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/21/2026		M		4,502	A	$55.18	96,868⁽¹⁾	D
Common Stock	01/21/2026		S⁽²⁾		4,502	D	$124.65⁽³⁾	92,366⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$55.18	01/21/2026		M⁽⁴⁾			2,602	⁽⁵⁾	03/24/2032	Common Stock	2,602	$0	62,411	D
Stock Option (Right to Buy)	$55.18	01/21/2026		M⁽⁴⁾			1,900	⁽⁶⁾	03/24/2032	Common Stock	1,900	$0	33,813	D

Explanation of Responses:

1. Includes 62,605 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

3. This transaction was executed in multiple trades at prices ranging from $124.47 to $124.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

5. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.

6. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.

	Diana Scherer, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GKOS president Joseph E. Gilliam report?

On January 21, 2026, Joseph E. Gilliam exercised stock options and acquired 4,502 Glaukos common shares at an exercise price of $55.18 per share, then sold 4,502 shares on the same day.

How many Glaukos (GKOS) shares did the insider sell and at what price?

Joseph E. Gilliam sold 4,502 Glaukos common shares at a weighted average price of $124.65 per share, with individual trades between $124.47 and $124.75.

Were the GKOS insider transactions made under a Rule 10b5-1 plan?

Yes. The reported sales and option exercises were carried out under a Rule 10b5-1 trading plan adopted by Joseph E. Gilliam on June 11, 2025.

How many Glaukos shares does the president & COO own after these transactions?

Following the reported transactions, Joseph E. Gilliam directly owns 92,366 shares of Glaukos common stock.

What portion of Joseph E. Gilliam’s GKOS holdings are restricted stock units?

His reported holdings include 62,605 restricted stock units that have not yet vested or been delivered.

What are the details of the Glaukos stock options exercised by the insider?

He exercised stock options covering 2,602 and 1,900 shares of Glaukos common stock at an exercise price of $55.18 per share, from grants dated March 24, 2022 that were tied to multi-year performance goals.